Correlation Between Nuvectis Pharma and Cullinan Oncology
Can any of the company-specific risk be diversified away by investing in both Nuvectis Pharma and Cullinan Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvectis Pharma and Cullinan Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nuvectis Pharma and Cullinan Oncology LLC, you can compare the effects of market volatilities on Nuvectis Pharma and Cullinan Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvectis Pharma with a short position of Cullinan Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvectis Pharma and Cullinan Oncology.
Diversification Opportunities for Nuvectis Pharma and Cullinan Oncology
0.4 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Nuvectis and Cullinan is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Nuvectis Pharma and Cullinan Oncology LLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cullinan Oncology LLC and Nuvectis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvectis Pharma are associated (or correlated) with Cullinan Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cullinan Oncology LLC has no effect on the direction of Nuvectis Pharma i.e., Nuvectis Pharma and Cullinan Oncology go up and down completely randomly.
Pair Corralation between Nuvectis Pharma and Cullinan Oncology
Given the investment horizon of 90 days Nuvectis Pharma is expected to generate 2.38 times more return on investment than Cullinan Oncology. However, Nuvectis Pharma is 2.38 times more volatile than Cullinan Oncology LLC. It trades about 0.0 of its potential returns per unit of risk. Cullinan Oncology LLC is currently generating about -0.13 per unit of risk. If you would invest 618.00 in Nuvectis Pharma on September 6, 2024 and sell it today you would lose (136.00) from holding Nuvectis Pharma or give up 22.01% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Nuvectis Pharma vs. Cullinan Oncology LLC
Performance |
Timeline |
Nuvectis Pharma |
Cullinan Oncology LLC |
Nuvectis Pharma and Cullinan Oncology Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Nuvectis Pharma and Cullinan Oncology
The main advantage of trading using opposite Nuvectis Pharma and Cullinan Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvectis Pharma position performs unexpectedly, Cullinan Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cullinan Oncology will offset losses from the drop in Cullinan Oncology's long position.Nuvectis Pharma vs. Replimune Group | Nuvectis Pharma vs. Lyra Therapeutics | Nuvectis Pharma vs. Kronos Bio | Nuvectis Pharma vs. Gossamer Bio |
Cullinan Oncology vs. Bolt Biotherapeutics | Cullinan Oncology vs. Day One Biopharmaceuticals | Cullinan Oncology vs. Lyra Therapeutics | Cullinan Oncology vs. Autolus Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
CEOs Directory Screen CEOs from public companies around the world | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |